
1. Lancet Respir Med. 2021 Dec 1. pii: S2213-2600(21)00538-5. doi:
10.1016/S2213-2600(21)00538-5. [Epub ahead of print]

Does the rise in seasonal respiratory viruses foreshadow the return of invasive
pneumococcal disease this winter?

Amin-Chowdhury Z(1), Bertran M(2), Sheppard CL(3), Eletu S(3), Litt D(3), Fry
NK(4), Ladhani SN(5).

Author information: 
(1)Immunisation and Vaccine-Preventable Diseases Division, UK Health Security
Agency, London NW9 5EQ, UK. Electronic address: zahin.amin@phe.gov.uk.
(2)Immunisation and Vaccine-Preventable Diseases Division, UK Health Security
Agency, London NW9 5EQ, UK.
(3)Respiratory and Vaccine Preventable Bacteria Reference Unit, UK Health
Security Agency, London NW9 5EQ, UK.
(4)Immunisation and Vaccine-Preventable Diseases Division, UK Health Security
Agency, London NW9 5EQ, UK; Respiratory and Vaccine Preventable Bacteria
Reference Unit, UK Health Security Agency, London NW9 5EQ, UK.
(5)Immunisation and Vaccine-Preventable Diseases Division, UK Health Security
Agency, London NW9 5EQ, UK; Paediatric Infectious Diseases Research Group
(PIDRG), St George's University of London, London, UK.

DOI: 10.1016/S2213-2600(21)00538-5 
PMID: 34863331 

Conflict of interest statement: CLS, SE, DL, and NKF report payment to their
institution for investigator-led research in pneumococcal pneumonia or carriage, 
or both, in humans by GlaxoSmithKline and Pfizer. All other authors declare no
competing interests.

